Economic Burden of Chronic Kidney Disease (CKD) in Type 2 Diabetes (T2D), Considering the Costs of Hospitalization Due to Heart Failure (HF) in Colombia
Author(s)
Claudia A. López-Cabra, MSc, Médica epidemióloga1, Ángela Daniela Rodríguez, MSc, Economist2, wilson Mayorga Mogollon, MSc, Economist2, Diana Smith Lopez, Esp., Economist2, Silvia Juliana Rey, Esp., Médica1, Laura Idrobo, Esp., Médica1, DIANA C. ACOSTA, Esp., Médica1, Diana Gutierrez, MD, Market Access1, Ruben D. Marrugo, MSc, Economist1;
1Bayer, Bogotá, Colombia, 2Numeris, Bogotá, Colombia
1Bayer, Bogotá, Colombia, 2Numeris, Bogotá, Colombia
Presentation Documents
OBJECTIVES: To estimate the economic burden of Chronic Kidney Disease (CKD) in Type 2 Diabetes (T2D), considering the standard of care and the costs of hospitalization due to heart failure (HF) in Colombia
METHODS: From a social perspective, the direct costs of the healthcare system (management of CKD and T2D considering HF hospitalization) and household costs were evaluated, as well as indirect costs using Disability-Adjusted Life Years (DALY) and the average income per worker. Direct costs per patient/year were calculated using a macro-costing approach. The hospitalization costs due to heart failure were weighted with the following probabilities (calculated using KDIGO 2024): 24,84% for microalbuminuria (30-300mg/24hrs), 42,1% for macroalbuminuria (>300mg/24hrs), and 94,67% for end-stage renal disease (ESRD). These values were used to conduct a cost and DALY simulation associated with disease progression using a Markov model, employing a transition matrix for a cohort of 1.000 patients aged 40 with T2D and a time horizon of 37 years, up to 77,23 years (Colombia’s life expectancy)
RESULTS: Using an exchange rate of COP$4.061 Colombian pesos per US dollar (USD), the total direct cost in US dollars for 2024 per patient/year was: USD$600 for microalbuminuria, USD$1.335 for macroalbuminuria and USD$11.204 for ESRD. The total healthcare system costs per patient/year were USD$567 for microalbuminuria, USD$882 for macroalbuminuria y USD$8.030 for ESRD, but those related only to HF hospitalization correspond to USD$454 for microalbuminuria, USD$769 for macroalbuminuria and USD$1.730 for ESRD. Out-of-pocket expenses were USD$33 for microalbuminuria, USD$452 for macroalbuminuria and USD$3.174 for ESRD per patient/year. The indirect costs were USD$526 for micro and macroalbuminuria, USD$2.888 for ESRD, and USD$5.059 in the death stage, with a total of 10,6 DALYs per person
CONCLUSIONS: The economic burden of CKD in T2D associated with hospitalization due to HF in Colombia is approximately USD$78.428 per patient in time horizon of 37 years
METHODS: From a social perspective, the direct costs of the healthcare system (management of CKD and T2D considering HF hospitalization) and household costs were evaluated, as well as indirect costs using Disability-Adjusted Life Years (DALY) and the average income per worker. Direct costs per patient/year were calculated using a macro-costing approach. The hospitalization costs due to heart failure were weighted with the following probabilities (calculated using KDIGO 2024): 24,84% for microalbuminuria (30-300mg/24hrs), 42,1% for macroalbuminuria (>300mg/24hrs), and 94,67% for end-stage renal disease (ESRD). These values were used to conduct a cost and DALY simulation associated with disease progression using a Markov model, employing a transition matrix for a cohort of 1.000 patients aged 40 with T2D and a time horizon of 37 years, up to 77,23 years (Colombia’s life expectancy)
RESULTS: Using an exchange rate of COP$4.061 Colombian pesos per US dollar (USD), the total direct cost in US dollars for 2024 per patient/year was: USD$600 for microalbuminuria, USD$1.335 for macroalbuminuria and USD$11.204 for ESRD. The total healthcare system costs per patient/year were USD$567 for microalbuminuria, USD$882 for macroalbuminuria y USD$8.030 for ESRD, but those related only to HF hospitalization correspond to USD$454 for microalbuminuria, USD$769 for macroalbuminuria and USD$1.730 for ESRD. Out-of-pocket expenses were USD$33 for microalbuminuria, USD$452 for macroalbuminuria and USD$3.174 for ESRD per patient/year. The indirect costs were USD$526 for micro and macroalbuminuria, USD$2.888 for ESRD, and USD$5.059 in the death stage, with a total of 10,6 DALYs per person
CONCLUSIONS: The economic burden of CKD in T2D associated with hospitalization due to HF in Colombia is approximately USD$78.428 per patient in time horizon of 37 years
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE232
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory), SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity), SDC: Urinary/Kidney Disorders